{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Continuous+Dose&page=97", "query": { "intervention": "Continuous Dose", "page": 97 }, "page_size": 10 }, "pagination": { "page": 97, "page_size": 10, "total_count": 5326, "total_pages": 533, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Continuous+Dose&page=98&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Continuous+Dose&page=96&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-14T08:29:43.320Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03422393", "title": "Venetoclax With High-dose Ibrutinib for CLL Progressing on Single Agent Ibrutinib", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Chronic Lymphocytic Leukemia", "Small Lymphocytic Lymphoma" ], "interventions": [ { "name": "Venetoclax", "type": "DRUG" }, { "name": "Ibrutinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Michael Choi", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2018-05-01", "completion_date": "2028-08", "has_results": false, "last_update_posted_date": "2024-07-05", "last_synced_at": "2026-11-14T08:29:43.320Z", "location_count": 1, "location_summary": "La Jolla, California", "locations": [ { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03422393" }, { "nct_id": "NCT01387204", "title": "Study to Investigate the Absorption, Distribution, Metabolism and Elimination of [14C]GSK1120212", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "GSK1120212", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 6, "start_date": "2011-02-15", "completion_date": "2011-07-18", "has_results": false, "last_update_posted_date": "2017-11-13", "last_synced_at": "2026-11-14T08:29:43.320Z", "location_count": 1, "location_summary": "Tacoma, Washington", "locations": [ { "city": "Tacoma", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT01387204" }, { "nct_id": "NCT00833495", "title": "Evaluation of Efficacy of Coadministration of FOV1101-00 and Prednisolone Acetate in Patients With Mild Ongoing Ocular Allergic Inflammation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Allergic Conjunctivitis" ], "interventions": [ { "name": "Prednisolone Acetate 0.12% (Pred Mild®)", "type": "DRUG" }, { "name": "FOV1101-00", "type": "DRUG" }, { "name": "Prednisolone Acetate 1% (Pred Forte®)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Fovea Pharmaceuticals SA", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 155, "start_date": "2009-01", "completion_date": "2009-03", "has_results": false, "last_update_posted_date": "2012-03-09", "last_synced_at": "2026-11-14T08:29:43.320Z", "location_count": 1, "location_summary": "Andover, Massachusetts", "locations": [ { "city": "Andover", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00833495" }, { "nct_id": "NCT00379639", "title": "A Study of Romidepsin (Depsipeptide) in Combination With Gemcitabine in Patients With Pancreatic and Other Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pancreatic Cancer" ], "interventions": [ { "name": "Romidepsin", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2006-07-01", "completion_date": "2008-07-01", "has_results": true, "last_update_posted_date": "2019-10-30", "last_synced_at": "2026-11-14T08:29:43.320Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00379639" }, { "nct_id": "NCT00448357", "title": "Allogeneic Hematopoietic Cell Transplantation for Patients With Busulfex-based Regimen", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Chronic Myeloproliferative Disorders", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes" ], "interventions": [ { "name": "rabbit anti-thymocyte globulin (ATG)", "type": "BIOLOGICAL" }, { "name": "therapeutic allogeneic lymphocytes", "type": "BIOLOGICAL" }, { "name": "busulfan", "type": "DRUG" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "tacrolimus", "type": "DRUG" }, { "name": "allogeneic hematopoietic stem cell transplantation", "type": "PROCEDURE" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" }, { "name": "methotrexate", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "UNC Lineberger Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 54, "start_date": "2005-10", "completion_date": "2015-11", "has_results": true, "last_update_posted_date": "2017-07-17", "last_synced_at": "2026-11-14T08:29:43.320Z", "location_count": 1, "location_summary": "Chapel Hill, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00448357" }, { "nct_id": "NCT02285101", "title": "Recombinant Human Arginase 1 (rhArg1) in Patients With Advanced Arginine Auxotrophic Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma", "Prostate Adenocarcinoma" ], "interventions": [ { "name": "PEG-BCT-100", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Bio-Cancer Treatment International Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 23, "start_date": "2014-11", "completion_date": "2019-02", "has_results": false, "last_update_posted_date": "2020-04-24", "last_synced_at": "2026-11-14T08:29:43.320Z", "location_count": 2, "location_summary": "San Diego, California • Santa Monica, California", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02285101" }, { "nct_id": "NCT03645928", "title": "Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Melanoma", "Squamous Cell Carcinoma of the Head and Neck", "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "Lifileucel", "type": "BIOLOGICAL" }, { "name": "LN-145", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "LN-145-S1", "type": "BIOLOGICAL" }, { "name": "Ipilimumab", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Nivolumab-relatlimab", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Nab paclitaxel", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Iovance Biotherapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 225, "start_date": "2019-05-07", "completion_date": "2026-02-20", "has_results": false, "last_update_posted_date": "2026-05-15", "last_synced_at": "2026-11-14T08:29:43.320Z", "location_count": 20, "location_summary": "La Jolla, California • Los Angeles, California • Denver, Colorado + 15 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT03645928" }, { "nct_id": "NCT00098865", "title": "Thalidomide and Temozolomide in Relapsed or Progressive CNS Disease or Neuroblastoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Central Nervous System Tumor, Pediatric", "Neuroblastoma" ], "interventions": [ { "name": "temozolomide", "type": "DRUG" }, { "name": "thalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 15, "start_date": "2002-09", "completion_date": "2010-06", "has_results": true, "last_update_posted_date": "2014-10-07", "last_synced_at": "2026-11-14T08:29:43.320Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00098865" }, { "nct_id": "NCT07699107", "title": "Adalimumab Dose Adjustment for Pediatric Uveitis Treatment Trial", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Juvenile Idiopathic Arthritis Associated Uveitis", "Uveitis, Anterior" ], "interventions": [ { "name": "Adalimumab/Biosimilar", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Nisha Acharya", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": null, "sex": "ALL", "summary": "2 Years and older" }, "enrollment_count": 160, "start_date": "2026-09", "completion_date": "2030-11", "has_results": false, "last_update_posted_date": "2026-07-13", "last_synced_at": "2026-11-14T08:29:43.320Z", "location_count": 9, "location_summary": "Los Angeles, California • Sacramento, California • San Francisco, California + 6 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Kansas City", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT07699107" }, { "nct_id": "NCT03161964", "title": "Propranolol in Treating Hypoglycemia Unawareness", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Type 1 Diabetes Mellitus" ], "interventions": [ { "name": "Propranolol 80 Mg Oral Capsule, Extended Release", "type": "DRUG" }, { "name": "Placebo oral capsule", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Anu Sharma", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": "59 Years", "sex": "ALL", "summary": "21 Years to 59 Years" }, "enrollment_count": 2, "start_date": "2017-10-19", "completion_date": "2019-12-19", "has_results": true, "last_update_posted_date": "2020-08-24", "last_synced_at": "2026-11-14T08:29:43.320Z", "location_count": 1, "location_summary": "Salt Lake City, Utah", "locations": [ { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT03161964" } ] }